Oxford, UK – 26 July 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, today announces that it has initiated a new project with Orchard Therapeutics utilising the Company’s proprietary LentiStable™ technology. As part of the project, Oxford Biomedica’s LentiStable™ technology platform… Read More
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory… Read More
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory… Read More
Oxford, UK – 14 June 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, notes the recent announcement from Homology Medicines Inc. (Nasdaq: FIXX) (“Homology”), a genetic medicines company regarding the pheNIX gene therapy trial. The U.S. Food and Drug Administration (FDA)… Read More
Bedford, Massachusetts – May 6, 2022: Oxford Biomedica Solutions, LLC. (“Oxford Biomedica Solutions”), a new high-performing, full scope AAV manufacturing and innovation business, now offering its ‘Plug & Play’ Platform that has successfully delivered four GMP programs and five Investigational New Drug submissions. Oxford Biomedica Solutions is announcing today that… Read More
London, UK – 27 April 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica”, “the Company” or “the Group”), a leading gene and cell therapy group, gives notice that copies of the 2021 Annual report and accounts and the… Read More
Saving Lives Oxford, UK – 20 April 2022: Oxford Biomedica plc (LSE:OXB), (“Oxford Biomedica” or “the Group”), a leading cell and gene therapy group, today announces its preliminary results for the year ended 31 December 2021. Dr. Roch Doliveux, Chair and Interim Chief Executive Officer of Oxford Biomedica, said: “I… Read More
Oxford, UK – 13 April 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, announces the appointment of Ms. Namrata P Patel to the Board as an Independent Non-Executive Director with immediate effect. Ms. Patel has extensive international experience in manufacturing and end… Read More
Unique platform offering capabilities from vector design and process development through to clinical trials is now available to new customers Oxford, UK – 11 March 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or the “Company”), a leading gene and cell therapy group, is pleased to announce that it has completed… Read More
This is a partner product. Visit the relevant partner website for further information. Read More
Oxford Biomedica and Homology Medicines to establish Oxford Biomedica Solutions LLC, a new US-based AAV manufacturing and innovation business Homology Medicines to receive $130 million from Oxford Biomedica to continue to advance its three clinical programmes and genetic medicines platform Oxford Biomedica to invest $50 million to fund… Read More
Oxford, UK – 17 January 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group” or “the Company”) a leading gene and cell therapy company, today announces that, after more than 13 years of service, John Dawson, Chief Executive Officer, has signalled to the Board his intention to retire from the… Read More